ABSTRACT
At an early stage of development, a drug substance is at high risk of being abandoned because of a number of factors. As a drug substance progresses toward actual registration, more extensive effort will be needed to identify some impurities, and is justified. The aim of this entry is to provide information on how impurities may be defined and identified and discuss mass spectrometry instrumentation, and also presents various charts reflecting clinical trials for further illustration of key concepts.
